Checkpoint Therapeutics (NASDAQ:CKPT) issued its quarterly earnings results on Thursday. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.13), Bloomberg Earnings reports. The company had revenue of $0.34 million during the quarter. Checkpoint Therapeutics had a negative net margin of 1,316.72% and a negative return on equity of 102.39%.
Shares of Checkpoint Therapeutics opened at $3.23 on Friday, MarketBeat.com reports. The company has a market capitalization of $106.29 million and a P/E ratio of -3.23. Checkpoint Therapeutics has a fifty-two week low of $3.23 and a fifty-two week high of $3.30.
Get Checkpoint Therapeutics alerts:
CKPT has been the subject of a number of research reports. Zacks Investment Research raised shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Wednesday, March 21st. ValuEngine raised shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Checkpoint Therapeutics in a report on Friday.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.